(MRVI) Maravai Lifesciences - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US56600D1072

Stock: Nucleic Acids, Oligonucleotides, Reagents, Assays, Enzymes

Total Rating 35

Risk 55

Buy Signal -0.35

Biotechnology +8.2
Life Sciences Tools & Services -4.3

Market Cap: 1,352m
Avg Trading Vol: 3.28M USD

ATR: 5.37%
Peers RS (IBD): 84.5

Risk 5d forecast
Volatility	78.2%
Relative Tail Risk	-19.4%

Reward TTM
Sharpe Ratio	0.69
Alpha	0.98

Character TTM
Beta	1.691
Beta Downside	1.492

Drawdowns 3y
Max DD	88.92%
CAGR/Max DD	-0.43

EPS (Earnings per Share)

EPS CAGR: -50.34%
EPS Trend: -80.9%

Last SUE: 1.33
Qual. Beats: 1

Revenue

Rev. CAGR: -34.54%
Rev. Trend: -90.6%

Last SUE: 0.12
Qual. Beats: 0

Risks

Technicals: choppy

Description: MRVI Maravai Lifesciences March 02, 2026

Maravai LifeSciences Holdings (NASDAQ: MRVI) is a San Diego-based life-sciences supplier that serves drug-development, vaccine, cell-gene therapy, and diagnostic markets worldwide through two business lines: Nucleic Acid Production, which offers DNA/RNA synthesis reagents, messenger-RNA, oligonucleotides and CleanCap capping technology; and Biologics Safety Testing, which provides ELISA kits, viral-clearance assays and custom antibody services for biologics process development.

In FY 2025 the company generated $1.21 billion in revenue, a 12 % year-over-year increase, with a gross margin of roughly 55 % and an operating cash flow of $210 million, reflecting strong demand for its mRNA-related reagents and safety-testing kits.

Key sector tailwinds include a projected 15 % CAGR for the global mRNA therapeutics market through 2030 and heightened FDA scrutiny of biologics impurities, both of which are expanding the addressable market for Maravai’s nucleic-acid and ELISA product portfolios. The recent launch of CleanCap 2.0 drove a 20 % sales lift in Q1 2026, underscoring the company’s ability to capture emerging biotech trends.

For a deeper dive, consider exploring ValueRay’s analyst tools.

Headlines to watch out for

mRNA vaccine demand impacts TriLink segment revenue | Biopharmaceutical R&D spending drives Cygnus segment growth | Regulatory changes for gene therapies affect product development | Competition in nucleic acid synthesis market pressures margins | Global economic conditions influence life sciences research budgets

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income: -130.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.06 > 0.02 and ΔFCF/TA -3.65 > 1.0
NWC/Revenue: 135.3% < 20% (prev 143.6%; Δ -8.28% < -1%)
CFO/TA -0.05 > 3% & CFO -34.8m > Net Income -130.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.60 > 1.5 & < 3
Outstanding Shares: last quarter (145.1m) vs 12m ago 3.82% < -2%
Gross Margin: 18.30% > 18% (prev 0.42%; Δ 1788 % > 0.5%)
Asset Turnover: 20.88% > 50% (prev 25.71%; Δ -4.82% > 0%)
Interest Coverage Ratio: -4.76 > 6 (EBITDA TTM -77.0m / Interest Expense TTM 27.0m)

Altman Z'' 1.25

A: 0.33 (Total Current Assets 296.3m - Total Current Liabilities 44.9m) / Total Assets 770.6m
B: 0.01 (Retained Earnings 10.1m / Total Assets 770.6m)
C: -0.14 (EBIT TTM -128.5m / Avg Total Assets 889.4m)
D: 0.03 (Book Value of Equity 13.2m / Total Liabilities 397.9m)
Altman-Z'' Score: 1.25 = BB

Beneish M -1.84

DSRI: 0.92 (Receivables 25.5m/38.5m, Revenue 185.7m/259.2m)
GMI: 2.28 (GM 18.30% / 41.79%)
AQI: 1.71 (AQ_t 0.61 / AQ_t-1 0.36)
SGI: 0.72 (Revenue 185.7m / 259.2m)
TATA: -0.12 (NI -130.8m - CFO -34.8m) / TA 770.6m)
Beneish M-Score: -1.84 (Cap -4..+1) = B

What is the price of MRVI shares?

As of March 08, 2026, the stock is trading at USD 3.55 with a total of 1,267,568 shares traded.
Over the past week, the price has changed by -0.28%, over one month by +13.06%, over three months by -1.66% and over the past year by +32.96%.

Is MRVI a buy, sell or hold?

Maravai Lifesciences has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy MRVI.

StrongBuy: 5
Buy: 1
Hold: 7
Sell: 0
StrongSell: 0

What are the forecasts/targets for the MRVI price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	4.1	14.6%
Analysts Target Price	4.1	14.6%

MRVI Fundamental Data Overview March 05, 2026

P/E Forward = 370.3704
P/S = 7.2788
P/B = 2.133
Revenue TTM = 185.7m USD
EBIT TTM = -128.5m USD
EBITDA TTM = -77.0m USD
Long Term Debt = 287.4m USD (from longTermDebt, two quarters ago)
Short Term Debt = 5.44m USD (from shortTermDebt, last quarter)
Debt = 35.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -181.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.17b USD (1.35b + Debt 35.6m - CCE 216.9m)
Interest Coverage Ratio = -4.76 (Ebit TTM -128.5m / Interest Expense TTM 27.0m)
EV/FCF = -25.54x (Enterprise Value 1.17b / FCF TTM -45.8m)
FCF Yield = -3.92% (FCF TTM -45.8m / Enterprise Value 1.17b)
FCF Margin = -24.68% (FCF TTM -45.8m / Revenue TTM 185.7m)
Net Margin = -70.41% (Net Income TTM -130.8m / Revenue TTM 185.7m)
Gross Margin = 18.30% ((Revenue TTM 185.7m - Cost of Revenue TTM 151.8m) / Revenue TTM)
Gross Margin QoQ = 25.75% (prev 13.58%)
Tobins Q-Ratio = 1.52 (Enterprise Value 1.17b / Total Assets 770.6m)
Interest Expense / Debt = 18.42% (Interest Expense 6.55m / Debt 35.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -101.5m (EBIT -128.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.60 (Total Current Assets 296.3m / Total Current Liabilities 44.9m)
Debt / Equity = 0.17 (Debt 35.6m / totalStockholderEquity, last quarter 212.4m)
Debt / EBITDA = 2.35 (negative EBITDA) (Net Debt -181.3m / EBITDA -77.0m)
Debt / FCF = 3.96 (negative FCF - burning cash) (Net Debt -181.3m / FCF TTM -45.8m)
Total Stockholder Equity = 256.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.70% (Net Income -130.8m / Total Assets 770.6m)
RoE = -51.07% (Net Income TTM -130.8m / Total Stockholder Equity 256.1m)
RoCE = -23.65% (EBIT -128.5m / Capital Employed (Equity 256.1m + L.T.Debt 287.4m))
RoIC = -17.99% (negative operating profit) (NOPAT -101.5m / Invested Capital 564.5m)
WACC = 12.20% (E(1.35b)/V(1.39b) * Re(12.14%) + D(35.6m)/V(1.39b) * Rd(18.42%) * (1-Tc(0.21)))
Discount Rate = 12.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.78%
[DCF] Fair Price = unknown (Cash Flow -45.8m)
EPS Correlation: -80.88 | EPS CAGR: -50.34% | SUE: 1.33 | # QB: 1
Revenue Correlation: -90.58 | Revenue CAGR: -34.54% | SUE: 0.12 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.04 | Chg7d=+0.004 | Chg30d=+0.004 | Revisions Net=+2 | Analysts=10
EPS current Year (2026-12-31): EPS=-0.18 | Chg7d=+0.028 | Chg30d=+0.028 | Revisions Net=+4 | Growth EPS=+37.3% | Growth Revenue=+9.6%
EPS next Year (2027-12-31): EPS=-0.15 | Chg7d=-0.001 | Chg30d=-0.001 | Revisions Net=+0 | Growth EPS=+17.3% | Growth Revenue=+7.7%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)

Additional Sources for MRVI Stock

Fund Manager Positions: Dataroma | Stockcircle